Recurrent meningiomas constitute an uncommon but significant problem after standard therapy failure. Speculation that meningiomas may be subject to endocrine influence was supported by both immunohistochemical analyses and epidemiological data. Therefore, alternative strategies such as endocrine therapy have been suggested. Although evidence of consistent findings for the role of specific hormonal exposures is mounting, there are numerous discrepancies about the mitogenic effect of hormonal manipulation on meningioma cells. A better understanding of the molecular mechanisms involved in meningioma pathogenesis may not only lead to the identification of novel diagnostic and prognostic markers but may also facilitate the development of new pathogenesis-based targeted strategies. This review of literature aims to summarize the present state-of-the-art of endocrine therapy in management of meningiomas, in order to establish whether hormonotherapy could be included in the therapeutic strategy for unresectable and/or progressive tumours in previously irradiated meningioma patients.
Introduction
Meningiomas are common tumours of the central nervous system that originate from the meningeal coverings of the spinal cord and the brain. Although the cell of origin has yet to be proven, meningiomas are probably derived from arachnoidal cap cells (Riemenschneider et al. 2006) . They constitute approximatively 13 to 26% of all intracranial tumors (Kleihues et al. 2002) . For most of those lesions, conventional strategy combining both surgery and radiation In the present report, the main goal was to establish whether hormonotherapy could be included in the therapeutic strategy for unresectable and/or progressive tumours in previously irradiated meningioma patients.
Literature review
An English-language literature search was conducted to identify all published studies assessing hormonal influences on meningiomas, in order to highlight potential prognostical and therapeutical value of endocrine therapy. Data for this review were identified by searches Page 3 of 27 
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of Medline and Cancerlit. The search terms 'meningioma', 'hormonotherapy', 'breast cancer', 'clinical trial' were used. References identified from within retrieved articles were also used.
There was no limitation on year of publication and no abstract forms were included.
Epidemiological background
The aetiology of primary brain tumours remains a controversial issue and the only somewhat Although a role of head injury for the induction of meningiomas has been suspected, this question cannot be answered definitely. It was suggested that the local alteration of the blood brain barrier might be involved by a consequent massive influx of cytokines into the extravasal space. Moreover, it was also advocated that several genes would be upregulated after traumatic brain injury, including genes controlling transcription regulation, signal transduction and intercellular adhesion (Michael et al. 2005 ).
In adults' meningiomas, epidemiological data have identified a ratio of 2:1 in female gender (Carroll et al. 2000) . Although a possible hormonal association between breast cancer and meningiomas has not been clarified, the simultaneous occurrence of meningiomas and breast cancer is an unusual but well-known event and several cases have been reported with or Page 4 of 27 5 without brain metastasis (Brandis et al. 1993 , Maiuri et al. 2002 , Markopoulos et al. 1998 ).
According to data from the Swedish Cancer Registry and from the United Stated Surveillance, Epidemiology and End Results (SEER) Program, (Ahsan et al. 1995 , Malmer et al. 2000 , the increased risk of developing meningioma was reported to be 1.5-1.7 times after breast cancer, with a mean time interval between the diagnosis of breast cancer and meningioma of 99.5 months.
Breast cancer and meningioma present some similar features that might account for their it is therefore of interest to delineate a possibility of hyperinsulinaemia as a triggering factor in both meningioma and breast cancer (Kaplan et al. 1997 ). Other authors hypothesized that because obesity affects male steroid hormone synthesis, male patients with meningiomas might exhibit a high obesity rate, suggesting a hormonal influence on meningiomas in men as well as women (Aghi et al. 2007 ).
Moreover, the human progesterone receptor (PgR) gene shares the same location as the mammary oncogene int-2 in chromosomal 11q13 (Law et al. 1987) . Although this proximity may explain the role of progesterone in breast cancer, the role of oncogene int-2 in the genesis of meningiomas is not yet known. Besides, both meningiomas and breast cancers overexpress Epidemiological background, including female predominance in meningiomas incidence, suggested that growth of meningiomas is hormone dependant. Growing evidence of an hormonal association between meningiomas and breast cancer incite to focus on the predictive value and therapeutic consequences of hormonal status in alternative strategies for patients with unresectable and/or already irradiated progressive meningioma. However, it is obvious that further studies remain necessary.
Hormonal receptors status and patients' outcome
It has been demonstrated that most of meningiomas express hormone receptors on their cell membranes, although to a variable extent (Marosi et al. 2008) . Actually, up to 90% of meningiomas express PgR, while fewer 30% to 48% express oestrogen receptors (ER) Olson et al. assessed hormonotherapy in specimens from 3 convexity meningiomas.
Mifepristone caused inhibition of cell growth in all three tumors, ranging from 18% to 36%.
These data were the first to suggest that selected meningiomas are subject to hormonal influence in vitro and encouraged further development of alternative modes of therapy for 
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visual field examination or improved CT or MRI scan) were noted in 8 patients, 7 of whom were male or premenopausal female, that can result in significant clinical benefit is this subgroup of patients (Grunberg et al. 2006) . The only prospective study on this topic was conducted on 160 patients. Eighty patients were treated with mifepristone 200mg and 80 patients were treated with placebo for a median duration of 10 months. Grade IV toxicities were experienced by 6 patients in the mifepristone arm, whereas one patient had grade IV toxicity in the placebo arm. Grade III toxicities were seen in 30 patients in the mifepristone arm and in 24 patients in the placebo arm. Most of reported toxicities were fatigue (72% versus 54%), headache (44% versus 41%), and hot flushes (38% versus 26%). Besides, several female patients developed endometrial hyperplasia. This trial was prematurely closed
and is yet to be published. Neither trend nor difference was observed between the 2 arms in terms of time to progression: 55% of patients had stable disease, 1% of patients had partial response and no patient could achieve complete response (Newfield et al. 2001) .
Tamoxifen is an orally active selective ER modulator which competitively binds to ER, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects.
Markwalder et al. reported 6 patients with meningiomas treated with tamoxifen and found no significant change in tumour growth with drug treatment (Markwalder et al. 1985) . In this small study, survival at 72 months was 72%, whereas it has been reported to be 71% with recommendation for the use of tamoxifen in refractory meningiomas could not be made (Goodwin et al. 1993) . Published data on meningiomas endocrine therapy in preclinical and clinical settings are reported in Table 1 .
From clinical results to molecular pathways
Steroid hormone receptors belong to a large superfamily of nuclear receptors that bind DNA at specific sites to control gene transcription (Savouret et al. 1991) . However, the mechanisms by which steroid receptors modulate the transcription of target genes remains under investigation. The existence of interactions between steroid hormones and peptide growth factors has also been reported (Murphy et al. 1986 ). After interaction with ligand, the receptors undergo conformational changes. Consequently, dimmers of receptors recognize specific regulatory DNA sequences upstream of several target genes. Activated receptors direct the assembly and the stabilization of a preinitiation complex that might conduct transcription of these genes (Carroll et al. 2000) . Several coactivators that are associated in a ligand-dependent manner have been identified, enhancing trans-activation of target genes (Horwitz et al. 1996) . It was demonstrated the expression of the steroid coactivators steroid receptor cofactor (SRC-1), amplified breast cancer protein (AIB1), and transcriptional intermediary factor 2 (TIF2) in most of meningiomas (Carroll et al. 2000) . Better (Lessey et al. 1983 , Graham et al. 1996 , they exhibit different regulating properties. PgR-A is considered to be a dominant negative transrepressor whereas PgR-B is a strong transactivator (Wen et al. 1994) . It was demonstrated that meningiomas contain both isoforms in variable ratios, but most of meningiomas express more PgR-A than PgR-B. This variability may have some biological significance. It was assumed that progesterone 
Conclusion
The place of hormonotherapy in meningioma remains unclear. Results from the present analysis of literature are that the PgR status combined with the routine pathological investigation can provide more insight in the behaviour of meningioma, particularly in histopathological borderline cases ). However, the PgR status alone cannot be used to predict behaviour in benign meningiomas and should not influence the decision about follow up intervals and therapeutic strategies. In the specific case of unresectable meningioma residue in progression after ionizing radiation, clinical chronology and data of literature incite to propose inclusion into a therapeutic trial. Understanding of 
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